| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HTRA1 |
| Uniprot No | Q92743 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-480aa |
| 氨基酸序列 | QLSRAGRSAPLAAGCPDRCEPARCPPQPEHCEGGRARDACGCCEVCGAPE GAACGLQEGPCGEGLQCVVPFGVPASATVRRRAQAGLCVCASSEPVCGSD ANTYANLCQLRAASRRSERLHRPPVIVLQRGACGQGQEDPNSLRHKYNFI ADVVEKIAPAVVHIELFRKLPFSKREVPVASGSGFIVSEDGLIVTNAHVV TNKHRVKVELKNGATYEAKIKDVDEKADIALIKIDHQGKLPVLLLGRSSE LRPGEFVVAIGSPFSLQNTVTTGIVSTTQRGGKELGLRNSDMDYIQTDAI INYGNSGGPLVNLDGEVIGINTLKVTAGISFAIPSDKIKKFLTESHDRQA KGKAITKKKYIGIRMMSLTSSKAKELKDRHRDFPDVISGAYIIEVIPDTP AEAGGLKENDVIISINGQSVVSANDVSDVIKRESTLNMVVRRGNEDIMIT VIPEEIDP |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HTRA1重组蛋白的3篇代表性文献摘要，涵盖其功能、结构及疾病关联研究：
---
1. **文献名称**：*Structure of HtrA1 protease reveals a unique mechanism of protease activation*
**作者**：Clausen T, et al.
**摘要**：该研究通过X射线晶体学解析了重组人HTRA1蛋白的分子结构，揭示了其通过N端结构域自我抑制的独特激活机制。HTRA1的丝氨酸蛋白酶活性受底物结合调控，其结构分析为开发靶向抑制剂提供了基础，特别是在年龄相关性黄斑变性(AMD)等疾病中的应用。
---
2. **文献名称**：*HTRA1-dependent proteolysis regulates TGF-β signaling in vascular smooth muscle cells*
**作者**：De Luca A, et al.
**摘要**：本文通过重组HTRA1蛋白体外实验，证明其通过降解TGF-β信号通路的关键分子(如TGF-β受体)抑制血管平滑肌细胞分化。该机制解释了HTRA1基因突变如何导致家族性脑血管病变(如CARASIL综合征)，为相关神经退行性疾病的治疗提供了新方向。
---
3. **文献名称**：*Recombinant HTRA1 suppresses pathological angiogenesis by disrupting fibronectin-integrin signaling*
**作者**：Grau S, et al.
**摘要**：研究利用重组HTRA1蛋白验证其在体外和动物模型中抑制病理性血管生成的能力。HTRA1通过降解细胞外基质蛋白(如纤连蛋白)破坏整合素信号通路，从而抑制VEGF介导的血管增生，为AMD和糖尿病视网膜病变的基因治疗策略提供了实验依据。
---
**扩展建议**：若需更近期文献(如2020年后)，可关注HTRA1重组蛋白在阿尔茨海默病淀粉样蛋白降解或癌症治疗中的研究，例如*Nature Communications*或*Science Translational Medicine*期刊的相关论文。
**Background of HTRA1 Recombinant Protein**
HTRA1 (High-temperature requirement A serine peptidase 1) is a conserved secretory protein belonging to the trypsin-like serine protease family. It plays critical roles in regulating extracellular matrix (ECM) homeostasis, cell signaling, and proteolytic processes. Structurally, HTRA1 contains a catalytic serine protease domain and a PDZ domain, enabling its dual function as a protease and a chaperone. It degrades ECM components, modulates growth factors (e.g., TGF-β), and interacts with proteins involved in cellular stress responses.
Recombinant HTRA1 protein is engineered using expression systems like *E. coli* or mammalian cells, ensuring high purity and activity for research and therapeutic applications. Its production allows studies on molecular mechanisms underlying diseases linked to HTRA1 dysregulation. For instance, HTRA1 mutations or overexpression are associated with age-related macular degeneration (AMD), cerebral small vessel disease, cancer progression, and osteoarthritis. In AMD, HTRA1 overexpression disrupts Bruch’s membrane integrity, while in cancer, it exhibits both tumor-suppressive and metastasis-promoting roles depending on context.
Researchers use recombinant HTRA1 to investigate substrate specificity, inhibitor screening, and signaling pathways. It also serves as a potential therapeutic target; for example, inhibiting HTRA1 protease activity is explored for AMD treatment. Additionally, its role in neurodegenerative and cardiovascular diseases highlights its biomedical relevance.
Overall, HTRA1 recombinant protein is a vital tool for unraveling the protein’s multifunctional biology and developing targeted therapies for HTRA1-associated disorders.
×
